Vivanza Biosciences Limited has formally notified BSE Limited regarding its non-applicability under the "Large Corporate" category as defined by regulatory circulars. The company confirmed that it does not meet the criteria for Large Corporate classification as of March 31, 2026.

Regulatory Compliance Confirmation

The company's communication to BSE Limited, dated April 9, 2026, specifically addresses compliance requirements under multiple regulatory frameworks. The confirmation relates to fund raising regulations for debt securities issuance by large corporates.

Regulatory Framework References

The company's confirmation references several key regulatory circulars that establish the framework for Large Corporate classification and associated disclosure requirements:

• SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018
• SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021 (updated April 13, 2022)
• BSE Circular No. LIST/COMP/05/2019-20 dated April 11, 2019
• BSE Circular No. LIST/COMP/59/2019-20 dated March 3, 2020
• BSE Notice No. 20220427-2 dated April 27, 2022

Disclosure Exemption Impact

Based on its non-Large Corporate status, Vivanza Biosciences Limited is exempt from filing specific disclosure requirements for FY26. The exemption covers Initial Disclosure filings under Annexure A as per BSE circulars and Annexure XII A under the SEBI operational circular.

Corporate Authorization

The formal communication was digitally signed by Chaitra Arora, Company Secretary & Compliance Officer, on April 9, 2026. The company has requested BSE Limited to take this confirmation on record for regulatory compliance purposes.

Vivanza biosciences Limited has fulfilled its regulatory compliance requirements by submitting the mandatory confirmation certificate under SEBI regulations for the fourth quarter of fiscal year 2026. The pharmaceutical company, based in Ahmedabad, completed this filing as part of its ongoing regulatory obligations to the stock exchanges.

Regulatory Compliance Filing

The company submitted its confirmation certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 to BSE Limited on April 7, 2026. This quarterly filing covers the period ended March 31, 2026 and was signed by Company Secretary Chaitra Arora.

Registrar and Transfer Agent Confirmation

Purva Sharegistry (I) Private Limited, serving as the company's Registrar and Share Transfer Agent, issued the confirmation certificate on April 1, 2026. The RTA holds SEBI registration number INR000001112 and operates as a Category 1 Registrar for IPOs and Share Transfer services.

The certificate confirms compliance with SEBI regulations regarding the processing of securities received from depository participants for dematerialization during the quarter. Ms. Deepali Gaonkar, Compliance Officer at Purva Sharegistry, signed the confirmation document.

Dematerialization Activity Report

The detailed dematerialization report for the period from January 1, 2026 to March 31, 2026 shows no activity during the quarter. The report indicates that no share certificates were processed for dematerialization during this period.

This quarterly filing demonstrates Vivanza Biosciences' commitment to maintaining regulatory compliance and transparent reporting to market participants and regulatory authorities.